1-[4-(dihydroxyboranyl)-3-methylphenyl]cyclopropane-1-carboxylic acid | 1628507-89-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[4-(dihydroxyboranyl)-3-methylphenyl]cyclopropane-1-carboxylic acid
• 英文别名: 1-[4-(Dihydroxyboranyl)-3-methylphenyl]cyclopropane-1-carboxylic acid；1-(4-borono-3-methylphenyl)cyclopropane-1-carboxylic acid
• CAS: 1628507-89-0
• 化学式: C₁₁H₁₃BO₄
• 分子量: 220.033
• InChiKey: GNYDSCKYOPJKTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.21
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-[2-(4-bromophenyl)-4-fluoro-2H-pyrazol-3-yl]carbamic acid 1-(2-chlorophenyl)ethyl ester 、 1-[4-(dihydroxyboranyl)-3-methylphenyl]cyclopropane-1-carboxylic acid 生成 (R)-1-(4'-{5-[1-(2-chlorophenyl)ethoxycarbonylamino]-4-fluoropyrazol-1-yl}-2-methylbiphenyl-4-yl)cyclopropanecarboxylic acid
  参考文献：
  名称：

  HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE

  摘要：

  本文介绍了一些杂环化合物，它们是溶磷脂酸受体配体，可用于治疗溶磷脂酸受体依赖性疾病和病症，包括但不限于涉及纤维化的疾病，如心脏、肾脏、肝脏和肺部纤维化，以及硬皮病；炎症性疾病，如糖尿病肾病和炎症性肠病；眼科疾病，如涉及视网膜退化的疾病；神经疾病，如瘙痒和疼痛。这些化合物的非限制性例子包括(RS)-3-环丙基-2-{4-[3-甲基-4((R)-1-苯基-乙氧羰基氨基)-异恶唑-5-基]-苄氧}-丙酸和(R)-1-(4′-{5-[1-(2-氯苯基)-乙氧羰基氨基]-4-氟吡唑-1-基}-2-氟联苯-4-基)-环丙烷羧酸。

  公开号：

  US20160024031A1

文献信息

• Discovery of biaryls as RORγ inverse agonists by using structure-based design
  作者：Istvan J. Enyedy、Noel A. Powell、Justin Caravella、Kurt van Vloten、Jianhua Chao、Daliya Banerjee、Douglas Marcotte、Laura Silvian、Andres McKenzie、Victor Sukbong Hong、Jason D. Fontenot

  DOI：10.1016/j.bmcl.2016.03.109

  日期：2016.5

  ROR gamma plays a critical role in controlling a pro-inflammatory gene expression program in several lymphocyte lineages including T cells, gamma delta T cells, and innate lymphoid cells. ROR gamma-mediated inflammation has been linked to susceptibility to Crohn's disease, arthritis, and psoriasis. Thus inverse agonists of ROR gamma have the potential of modulating inflammation. Our goal was to optimize two ROR gamma inverse agonists: T0901317 from literature and 1 that we obtained from internal screening. We used information from internal X-ray structures to design two libraries that led to a new biaryl series. (C) 2016 Elsevier Ltd. All rights reserved.
• HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE
  申请人：EPIGEN BIOSCIENCES, INC.

  公开号：US20160024031A1

  公开（公告）日：2016-01-28

  Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain. Non-limiting examples of those compounds include (RS)-3-Cyclopropyl-2-4-[3-methyl-4((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propionic acid and (R)-1-(4′-5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid.

  本文介绍了一些杂环化合物，它们是溶磷脂酸受体配体，可用于治疗溶磷脂酸受体依赖性疾病和病症，包括但不限于涉及纤维化的疾病，如心脏、肾脏、肝脏和肺部纤维化，以及硬皮病；炎症性疾病，如糖尿病肾病和炎症性肠病；眼科疾病，如涉及视网膜退化的疾病；神经疾病，如瘙痒和疼痛。这些化合物的非限制性例子包括(RS)-3-环丙基-2-4-[3-甲基-4((R)-1-苯基-乙氧羰基氨基)-异恶唑-5-基]-苄氧}-丙酸和(R)-1-(4′-5-[1-(2-氯苯基)-乙氧羰基氨基]-4-氟吡唑-1-基}-2-氟联苯-4-基)-环丙烷羧酸。